Table 1.

Sera positive for anti-drug antibodies of patients treated with A) IFX or B) ADL. Patient sera were analyzed by a certified ELISA system for anti-drug antibodies (not resolving the isotype).

A) Infliximab-treated patients
ID	anti-IFX [µg/mL]	IFX serum c [µg/mL]	ICRIP result
IFX438	54.1	< 4.0	ADL/IFX/IFX PI/bov TG
IFX452	63.9	4.9	bov TG
IFX485	74.1	18.3	neg.
IFX522	45.9	5.6	neg.
IFX638	39.3	< 4.0	neg.
IFX648	34.2	11.6	neg.
IFX652	29.7	< 4.0	neg.
IFX660	14.4	9.9	bov TG
IFX694	45.6	18.9	ADL PI/bov TG
IFX719	69.7	6.7	neg.
IFX721	> 80	11.4	neg.
IFX722	44.8	4.7	neg.
IFX724	32.6	< 4.0	neg.
IFX729	27.3	< 4.0	neg.
IFX752	18.8	< 4.0	neg.
IFX754	22.0	< 4.0	IFX/IFX PI
IFX767	67.5	26.1	neg.
IFX790	34.6	8.3	bov TG
IFX809	31.0	4.6	neg.
IFX883	46.1	< 4.0	neg.
IFX890	> 80	16.9	hu TG
IFX905	22.6	< 4.0	neg.
IFX922	> 80	21.3	IFX/bov TG
IFX928	59.9	7.6	neg.
IFX957	> 80	12.3	neg.
IFX963	73.9	28.0	neg.
IFX977	> 80	9.9	neg.
IFX982	29.4	< 4.0	neg.
IFX990	> 80	16.6	neg.
IFX996	> 80	20.5	neg.
B) Adalimumab-treated patients
ID	anti-ADL [µg/mL]	ADL serum c [µg/mL]	ICRIP result
ADL41	2.4	13.6	n.t.
ADL67	12.1	> 256	n.t.
ADL72	18.5	> 256	n.t.
ADL86	5.7	> 256	CTX/HSA-α-Gal/bov TG
ADL89	22.4	> 256	n.t.
ADL90	2.3	< 4.0	n.t.
ADL122	8.7	4.2	n.t.
ADL123	14.2	> 256	n.t.
ADL134	34.9	28.3	n.t.
ADL138	< 1.25	n.a.	neg.
ADL145	< 1.25	n.a.	neg.
ADL149	7.6	7.7	CTX
ADL176	18.1	> 256	ADL/ADL PI
ADL178	> 40	12.7	CTX/bov TG/hu TG
ADL197	11.8	< 4.0	ADL/bov TG
ADL198	12.7	< 4.0	ADL/bov TG
ADL216	1.8	< 4.0	neg.
ADL242	3.4	< 4.0	n.t.
ADL245	2.9	< 4.0	neg.

ICRIP results are shown according to results in Fig. 2. For abbreviations of ICRIP analytes see Fig. 1. neg.: negative; n.a.: not available; n.t.: not tested (due to lack of sera).